Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Zostavax vs HZ/su in Older Adults
NCT02114333Phase 1Completed
- Sponsor
- University of Colorado Denver
- Start
- May 2014
- Primary completion
- Mar 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of Zoster vaccine recombinant in herpes zoster (HZ) (4 arms), sponsored by University of Colorado Denver. Primary endpoint: Changes in Interferon gamma/ Interleukin 2 (IFNg/IL2) dual color fluorospot number at Day 730. Started May 2014; status: completed.
02
Drugs
Zoster vaccine recombinant
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT02114333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02114333.